Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
OBJECTIVE: Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) have increased risk for disease activity. Anti-CD20 IgG1 monoclonal antibodies (mAb) are increasingly used as disease-modifying therapies (DMTs). Patients may wish to both breastfeed and resume DMT postpartum. This study aimed to determine the transfer of anti-CD20 IgG1 mAbs, ocrelizumab, and rituximab (OCR/RTX), into mature breastmilk and describe maternal and infant outcomes.
METHODS: Fifty-seven cis-women receiving OCR/RTX after 59 pregnancies and their infants were enrolled and followed up to 12M postpartum or 90 days post-infusion. Breastmilk was collected pre-infusion and serially up to 90 days and assayed for mAb concentration. Medical records and patients' questionnaire responses were obtained to assess neurologic, breastfeeding, and infant development outcomes.
RESULTS: The median average concentration of mAb in breastmilk was low (OCR: 0.08 μg/mL, range 0.05-0.4; RTX: 0.03 μg/mL, range 0.005-0.3). Concentration peaked 1-7 days post-infusion in most (77%) and was nearly undetectable after 90 days. Median average relative infant dose was <1% (OCR: 0.1%, range 0.07-0.7; RTX: 0.04%, range 0.005-0.3). Forty-three participants continued to breastfeed post-infusion. At 8-12 months, the proportion of infants' growth between the 3rd and 97th World Health Organization percentiles did not differ for breastfed (36/40) and non-breastfed (14/16, p > 0.05) infants; neither did the proportion with normal development (breastfed: 37/41, non-breastfed: 11/13; p > 0.05). After postpartum infusion, two mothers experienced a clinical relapse.
INTERPRETATION: These confirm minimal transfer of mAb into breastmilk. Anti-CD20 mAb therapy stabilizes MS activity before conception to the postpartum period, and postpartum treatments appears to be safe and well-tolerated for both mother and infant.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Annals of clinical and translational neurology - 10(2023), 11 vom: 06. Nov., Seite 2053-2064 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anderson, Annika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4F4X42SYQ6 |
|---|
| Anmerkungen: |
Date Completed 16.11.2023 Date Revised 24.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/acn3.51893 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361734646 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361734646 | ||
| 003 | DE-627 | ||
| 005 | 20240324234804.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acn3.51893 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM361734646 | ||
| 035 | |a (NLM)37675826 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Anderson, Annika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.11.2023 | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a OBJECTIVE: Postpartum, patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) have increased risk for disease activity. Anti-CD20 IgG1 monoclonal antibodies (mAb) are increasingly used as disease-modifying therapies (DMTs). Patients may wish to both breastfeed and resume DMT postpartum. This study aimed to determine the transfer of anti-CD20 IgG1 mAbs, ocrelizumab, and rituximab (OCR/RTX), into mature breastmilk and describe maternal and infant outcomes | ||
| 520 | |a METHODS: Fifty-seven cis-women receiving OCR/RTX after 59 pregnancies and their infants were enrolled and followed up to 12M postpartum or 90 days post-infusion. Breastmilk was collected pre-infusion and serially up to 90 days and assayed for mAb concentration. Medical records and patients' questionnaire responses were obtained to assess neurologic, breastfeeding, and infant development outcomes | ||
| 520 | |a RESULTS: The median average concentration of mAb in breastmilk was low (OCR: 0.08 μg/mL, range 0.05-0.4; RTX: 0.03 μg/mL, range 0.005-0.3). Concentration peaked 1-7 days post-infusion in most (77%) and was nearly undetectable after 90 days. Median average relative infant dose was <1% (OCR: 0.1%, range 0.07-0.7; RTX: 0.04%, range 0.005-0.3). Forty-three participants continued to breastfeed post-infusion. At 8-12 months, the proportion of infants' growth between the 3rd and 97th World Health Organization percentiles did not differ for breastfed (36/40) and non-breastfed (14/16, p > 0.05) infants; neither did the proportion with normal development (breastfed: 37/41, non-breastfed: 11/13; p > 0.05). After postpartum infusion, two mothers experienced a clinical relapse | ||
| 520 | |a INTERPRETATION: These confirm minimal transfer of mAb into breastmilk. Anti-CD20 mAb therapy stabilizes MS activity before conception to the postpartum period, and postpartum treatments appears to be safe and well-tolerated for both mother and infant | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Rituximab |2 NLM | |
| 650 | 7 | |a 4F4X42SYQ6 |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Rowles, William |e verfasserin |4 aut | |
| 700 | 1 | |a Poole, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Balan, Ayushi |e verfasserin |4 aut | |
| 700 | 1 | |a Bevan, Carolyn |e verfasserin |4 aut | |
| 700 | 1 | |a Brandstadter, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Ciplea, Andrea I |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Joanna |e verfasserin |4 aut | |
| 700 | 1 | |a Fabian, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Hale, Thomas W |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobs, Dina |e verfasserin |4 aut | |
| 700 | 1 | |a Kakara, Mihir |e verfasserin |4 aut | |
| 700 | 1 | |a Krysko, Kristen M |e verfasserin |4 aut | |
| 700 | 1 | |a Longbrake, Erin E |e verfasserin |4 aut | |
| 700 | 1 | |a Marcus, Jacqueline |e verfasserin |4 aut | |
| 700 | 1 | |a Repovic, Pavle |e verfasserin |4 aut | |
| 700 | 1 | |a Riley, Claire S |e verfasserin |4 aut | |
| 700 | 1 | |a Romeo, Andrew R |e verfasserin |4 aut | |
| 700 | 1 | |a Rutatangwa, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a West, Timothy |e verfasserin |4 aut | |
| 700 | 1 | |a Hellwig, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a LaHue, Sara C |e verfasserin |4 aut | |
| 700 | 1 | |a Bove, Riley |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and translational neurology |d 2014 |g 10(2023), 11 vom: 06. Nov., Seite 2053-2064 |w (DE-627)NLM234874031 |x 2328-9503 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:11 |g day:06 |g month:11 |g pages:2053-2064 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acn3.51893 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 11 |b 06 |c 11 |h 2053-2064 | ||